Dehydrated Human Amnion/Chorion Membrane to Treat Venous Leg Ulcers: A Cost-Effectiveness Analysis
Summary: Markov model (3-year horizon, Medicare perspective) compared dHACM following parameters for use (FPFU: initiated 30-45 days post-diagnosis, weekly/biweekly) vs no advanced treatment (NAT) for VLUs. dHACM dominated: -$170 per-patient costs, +0.010 QALYs; NMB $1178 ($100k/QALY threshold). Cost-effective 63% PSA simulations. Recurrence rates key uncertainty driver; supports dHACM reimbursement for qualifying VLUs.
Key Highlights:
- Outcomes: Cost-saving + QALY gain → dominance.
- NMB: $1178 favor dHACM.
- PSA: 63% cost-effective at $100k threshold.
- Model: 4-state Markov; real-world data.
- Authors: Not specified in summary.
Keywords: dHACM, VLU, cost-effectiveness, Markov, Medicare